Project Grant R44AG060826

This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $3,357,206 to Allyx Therapeutics Inc. to conduct clinical evaluation of the drug BMS-984923 for the treatment of Alzheimer's disease (AD). The project aims to develop a novel disease-modifying compound that targets the underlying mechanism of synapse loss, a key driver of cognitive decline in AD. Preliminary studies have demonstrated the drug's efficacy in preclinical mouse models, where...

The U.S. National Institute on Aging (NIA) has awarded a $3,474,488 Cooperative Agreement under the Aging Research Grant Program (CFDA 93.866) to Emory University to develop a small-molecule antagonist of the EP2 receptor as a potential disease-modifying treatment for Alzheimer's disease (AD). The project aims to define the pharmacokinetic and pharmacodynamic (PK/PD) relationships of the lead EP2 antagonist candidates on AD pathology markers in two different mouse models of early-onset and...

This $9,082,796 Project Grant award from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) supports a clinical trial conducted by Banner Health in Phoenix, AZ. The trial will evaluate the efficacy of a plaque-clearing antibody (PCA) treatment and a gamma secretase modulator (GSM) treatment, alone and in combination, in reducing brain amyloid levels in 200 cognitively unimpaired and mildly impaired participants with the PSEN1 E280A Alzheimer's disease...

This $804,450 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to investigate the mechanisms behind the selective neuronal dysfunction and vulnerability caused by the Alzheimer's disease genetic risk factor ApoE4. The research project, led by the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco, California, will leverage cutting-edge methods including single-nucleus RNA sequencing and in-vivo brain...

This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $4,694,672 to North Dakota State University from May 15, 2021 through April 30, 2024. The funding supports research to design a non-viral gene delivery system for delivering an APOE2 plasmid to the brain. Specifically, the university will synthesize and characterize liposomal nanoparticles loaded with chitosan-APOE2 polyplexes and modified with transferrin and cell-penetrating peptides...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,883 to Degrome Therapeutics, Inc. to develop small-molecule degraders of the amyloid precursor protein (APP) as novel therapeutics for Alzheimer's disease (AD). The project aims to optimize these APP degrader compounds to improve their potency, solubility, and blood-brain barrier permeability, with the goal of identifying lead candidates for further preclinical development and potential...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, is focused on developing a novel phosphorodiamidate morpholino oligonucleotide (PMO) RNA therapeutic to treat Alzheimer's disease (AD). The $238,500 award, running from December 1, 2024 to November 30, 2026, aims to create a highly effective PMO therapeutic that can selectively target the amyloid precursor protein (APP) to prevent the buildup of amyloid...

The Sanford Burnham Prebys Medical Discovery Institute was awarded a $1,649,586 Project Grant from the National Institute on Aging (CFDA 93.866 - Aging Research) to discover and optimize APOE4 correctors for the treatment of Alzheimer's disease. The award runs from August 1, 2024 to July 31, 2029. The key focus of this project is to develop small molecule compounds that can bind to the APOE4 protein and functionally correct it to resemble the APOE3 variant, which is associated with a lower...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $835,417.00 to the Icahn School of Medicine at Mount Sinai to develop novel lipid nanoparticle (LNP) formulations for the efficient delivery of nucleic acid therapeutics across the blood-brain barrier to treat Alzheimer's disease. The key objectives are to synthesize BBB-crossing lipids, formulate a library of LNPs, and engineer siRNA and mRNA sequences to modulate APOE4 and APOE2 gene...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,041,646 to Cenna Biosciences Inc. to support the early clinical development of their modified P8 peptide drug candidate for the treatment of Alzheimer's disease. The key products and services to be delivered under this grant include: 1) Chemistry, Manufacturing, and Controls (CMC) activities to support clinical development of the drug product, 2) a pre-IND meeting with the FDA and...